56243-25-5

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-4-cyano-4-phenylpiperidine hydrochloride is used as a calcium channel blocker for the treatment of various cardiovascular conditions. Its chemical structure allows it to interact with calcium channels in the heart and blood vessels, leading to a reduction in blood pressure and improved cardiovascular function.
Used in Chemical Research:
As a piperidine derivative, 1-Benzyl-4-cyano-4-phenylpiperidine hydrochloride is also used in chemical research and development. Its unique properties make it a valuable compound for studying the effects of structural modifications on the activity and selectivity of various chemical and biological processes.
Used in Drug Synthesis:
1-Benzyl-4-cyano-4-phenylpiperidine hydrochloride can be utilized as an intermediate in the synthesis of other pharmaceuticals and active ingredients. Its off-white crystalline solid form makes it suitable for various chemical reactions and processes, contributing to the development of new drugs and therapies.

InChI:InChI=1/C19H20N2/c20-16-19(18-9-5-2-6-10-18)11-13-21(14-12-19)15-17-7-3-1-4-8-17/h1-10H,11-15H2/p+1

Upstream product

• 40481-13-8 4-phenyl-4-cyanopiperidine 
• 100-39-0 benzyl bromide 
• 51304-58-6 4-cyano-4-phenylpiperidine hydrochloride 
• 100-46-9 benzylamine 
• 140-29-4 phenylacetonitrile 
• 75-21-8 oxirane 
• 101-32-6 N-benzyl-diethanolamine 
• 10469-27-9 α,α-bis(2-hydroxyethyl)phenylacetonitrile 
• 100119-73-1 1,5-dichloro-3-cyano-3-phenylpentane 
• 55-51-6 N,N-bis(2-chloro-ethyl)-benzenemethanamine 

Downstream Products

• 199439-86-6 1-Benzyl-1-oxy-4-phenyl-piperidine-4-carboxylic acid amide 
• 59084-08-1 1-benzyl-4-phenyl-piperidine-4-carboxylic acid ethyl ester 
• 538324-30-0 3-[4-(4-bromo-phenyl)-piperidin-4-yl]-propionic acid methyl ester 
• 904283-17-6 3-(1-benzyl-4-phenyl-piperidin-4-yl)-propionic acid methyl ester 
• 538324-33-3 4-(4-bromo-phenyl)-4-(2-methoxycarbonyl-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 538324-34-4 4-(4-bromo-phenyl)-4-[2-(3,4-difluoro-phenylcarbamoyl)-ethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 538323-78-3 4-(3'-cyano-biphenyl-4-yl)-4-[2-(3,4-difluoro-phenylcarbamoyl)-ethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 761355-17-3 (4-phenylpiperidin-4-yl)methanamine 
• 873403-64-6 (4-phenyl-[4]piperidylmethyl)-urea 
• 102156-18-3 1-(1-benzyl-4-phenyl-[4]piperidyl)-ethanone 
• 873403-55-5 (1-benzyl-4-phenyl-[4]piperidylmethyl)-urea 
• 83898-31-1 (1-benzyl-4-phenyl-[4]piperidylmethyl)-carbamic acid ethyl ester 
• 936855-38-8 C₁₉H₂₃N₃O 

Relevant academic research and scientific papers

A 4-substituted piperidine derivatives synthetic method

The invention relates to a synthesis method of 4-substituted piperidine derivatives. The synthesis method comprises the following steps: continuously reacting alpha-single substituted acetonitrile serving as a raw material with two-molecular ethylene oxide in the presence of a base I, thereby synthesizing compounds (2), wherein not one compound (2) is generated, and the compounds (2) are in tautomeric equilibrium with a compound (6); breaking the balance in the presence of a base II to generate an alcoxyl negative ion compound (3); reacting the compound (3) with R2SO2X or (R2SO2)2O to generate sulphonates (4); performing a cyclization reaction on the sulphonates (4) and primary amine to synthesize 4-substituted piperidine derivatives. Compared with a document reported method, the synthesis method has the advantages that the reaction steps are shortened and the synthetic efficiency is improved.

Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities

A new series of thiazole-substituted 1,1,1,3,3,3-hexafluoro-2-propanols were prepared and evaluated as malonyl-CoA decarboxylase (MCD) inhibitors. Key analogs caused dose-dependent decreases in food intake and body weight in obese mice. Acute treatment with these compounds also led to a drop in elevated blood glucose in a murine model of type II diabetes.

A convenient one-pot preparation of N-substituted 4-phenylpiperidines

N-Substituted 4-phenylpiperidines were readily synthesized by one-pot cyclization of diols with amines via bis-triflate intermediates. The new synthesis under mild conditions gave various N-substituted 4-phenylpiperidines in moderate to good yields.

Nitrile analogs of meperidine as high affinity and selective sigma-1 receptor ligands

A series of N-substituted-4-cyano-4-phenylpiperidine analogs were synthesized and evaluated for binding affinity at opioid receptors and showed no affinity. The series similarity to previously reported σ ligands prompted analysis at σ receptors to determine the SAR for affinity at σ receptors. Within the N-substituent series the saturated analogs showed increased affinity at both σ receptors. Optimal chain length in the N-arylalkyl series for σ1 and σ2 receptors proved to be N-propylphenyl; extension to a four carbon chain dramatically decreased affinity at both receptors. Substituents in the 4-position affect only σ1 affinity; no change in affinity at σ2 was shown. The N-isobutyl, N-phenylpropyl, and N-benzyl analogs are worth pursuing due to their good affinity and selectivity at the σ1 receptor, whereas the N-benzyl analog exhibits the greatest selectivity for σ1.

Opioids and efflux transporters. Part 1: P-Glycoprotein substrate activity of N-substituted analogs of meperidine

P-Glycoprotein (P-gp) is an efflux transporter which is up-regulated at the blood-brain barrier in both morphine- and oxycodone-tolerant rats. Numerous studies have shown that many clinically employed opioid analgesics are substrates for P-gp, suggesting that up-regulation of P-gp may contribute to the development of central tolerance to opioids. The studies herein focus on the development of SAR for P-gp substrate activity in the meperidine series of compounds, and show that a meperidine analog of greater potency, N-phenylbutyl-N-normeperidine, has low activity as a P-gp substrate and has the potential to be utilized as a tool to study the contribution of P-gp to the development of central tolerance to opioids.

NOVEL HETEROCYCLIC SUBSTITUTED PYRROLIDINE AMIDE DERIVATIVES

The present invention relates to novel heterocyclic substituted pyrrolidine amide derivatives of formula (1), and stereoisomers and pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, cough, and bronchitis.

Compounds with analgesic and local anaesthetic effect

New compounds of the formula (A) STR1 a process for their preparation and their use in the manufacture of pharmaceutical preparations. The new compounds have both local anaesthetic and analgesic effect.